News August 28, 2017 - DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial — Dalcetrapib Studied in Genetically Targeted Patients with Acute Coronary Syndrome — Read More August 1, 2017 - ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial Read More July 27, 2017 - PreciThera Inc. Completes $36 Million Series A Financing: Funding to Develop Novel Biologics Targeting Orphan Bone Diseases into Clinical Trials Read More June 15, 2017 - ViaCyte Presents at the ISSCR 2017 Annual Meeting in Boston Read More June 1, 2017 - Can DalCor Pharma Succeed Where Others Have Failed? Read More May 27, 2017 - Sotera® Wireless To Spotlight Surveillance Monitoring For Patient Safety At AAMI 2016 Read More May 24, 2017 - CalciMedica Receives Fast-Track Designation For CM4620, A Novel CRAC Channel Inhibitor To Treat Acute Pancreatitis Read More May 22, 2017 - ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes Read More May 22, 2017 - JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes Read More May 22, 2017 - ViaCyte Announces $10 Million in Financing Read More